B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells.

ATAC-seq B4GALT1 CSCs LUAD NSCLC RNA-seq cancer stem cells genome-wide lung cancer transcriptome

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
09 Nov 2019
Historique:
received: 16 09 2019
revised: 30 10 2019
accepted: 05 11 2019
entrez: 14 11 2019
pubmed: 14 11 2019
medline: 14 11 2019
Statut: epublish

Résumé

According to the cancer stem cells (CSCs) hypothesis, a population of cancer cells with stem cell properties is responsible for tumor propagation, drug resistance, and disease recurrence. Study of the mechanisms responsible for lung CSCs propagation is expected to provide better understanding of cancer biology and new opportunities for therapy. The Lung Adenocarcinoma (LUAD) NCI-H460 cell line was grown either as 2D or as 3D cultures. Transcriptomic and genome-wide chromatin accessibility studies of 2D vs. 3D cultures were carried out using RNA-sequencing and Assay for Transposase Accessible Chromatin with high-throughput sequencing (ATAC-seq), respectively. Reverse transcription polymerase chain reaction (RT-PCR) was also carried out on RNA extracted from primary cultures derived from malignant pleural effusions to validate RNA-seq results. RNA-seq and ATAC-seq data disentangled transcriptional and genome accessibility variability of 3D vs. 2D cultures in NCI-H460 cells. The examination of genomic landscape of genes upregulated in 3D vs. 2D cultures led to the identification of 2D cultures led to the identification of Beta-1,4-galactosyltranferase 1 (B4GALT1) as the top candidate. B4GALT1 as the top candidate. B4GALT1 was validated as a stemness factor, since its silencing caused strong inhibition of 3D spheroid formation. Combined transcriptomic and chromatin accessibility study of 3D vs. 2D LUAD cultures led to the identification of B4GALT1 as a new factor involved in the propagation and maintenance of LUAD CSCs.

Sections du résumé

BACKGROUND BACKGROUND
According to the cancer stem cells (CSCs) hypothesis, a population of cancer cells with stem cell properties is responsible for tumor propagation, drug resistance, and disease recurrence. Study of the mechanisms responsible for lung CSCs propagation is expected to provide better understanding of cancer biology and new opportunities for therapy.
METHODS METHODS
The Lung Adenocarcinoma (LUAD) NCI-H460 cell line was grown either as 2D or as 3D cultures. Transcriptomic and genome-wide chromatin accessibility studies of 2D vs. 3D cultures were carried out using RNA-sequencing and Assay for Transposase Accessible Chromatin with high-throughput sequencing (ATAC-seq), respectively. Reverse transcription polymerase chain reaction (RT-PCR) was also carried out on RNA extracted from primary cultures derived from malignant pleural effusions to validate RNA-seq results.
RESULTS RESULTS
RNA-seq and ATAC-seq data disentangled transcriptional and genome accessibility variability of 3D vs. 2D cultures in NCI-H460 cells. The examination of genomic landscape of genes upregulated in 3D vs. 2D cultures led to the identification of 2D cultures led to the identification of Beta-1,4-galactosyltranferase 1 (B4GALT1) as the top candidate. B4GALT1 as the top candidate. B4GALT1 was validated as a stemness factor, since its silencing caused strong inhibition of 3D spheroid formation.
CONCLUSION CONCLUSIONS
Combined transcriptomic and chromatin accessibility study of 3D vs. 2D LUAD cultures led to the identification of B4GALT1 as a new factor involved in the propagation and maintenance of LUAD CSCs.

Identifiants

pubmed: 31717588
pii: jcm8111928
doi: 10.3390/jcm8111928
pmc: PMC6912435
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG17007
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG15216
Organisme : Regione Lazio
ID : 85-2017- 13750
Organisme : Facoltà di Medicina e Psicologiaa, Sapienza Università di Roma
ID : B86C19001510005

Références

Oncogene. 2017 Aug 10;36(32):4671-4672
pubmed: 28628115
Bioinformatics. 2016 Jun 15;32(12):i192-i200
pubmed: 27307617
Semin Cancer Biol. 2019 Aug;57:27-35
pubmed: 31276784
BMC Cancer. 2018 May 24;18(1):590
pubmed: 29793447
BMC Cancer. 2017 Apr 12;17(1):261
pubmed: 28403887
Oncogene. 2018 May;37(18):2367-2378
pubmed: 29445137
Cancers (Basel). 2019 Oct 19;11(10):
pubmed: 31635093
Trends Endocrinol Metab. 2017 Dec;28(12):831-842
pubmed: 29089222
Genes Chromosomes Cancer. 2012 Dec;51(12):1133-43
pubmed: 22927297
Pathol Int. 2016 Nov;66(11):601-608
pubmed: 27510923
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Nature. 2015 Aug 13;524(7564):225-9
pubmed: 26123021
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Genome Res. 2019 May;29(5):723-736
pubmed: 30962179
IUBMB Life. 2012 Nov;64(11):889-900
pubmed: 23024026
Food Chem Toxicol. 2015 Feb;76:77-9
pubmed: 25483621
Cell. 2017 Dec 14;171(7):1573-1588.e28
pubmed: 29224777
PLoS Genet. 2013;9(1):e1003225
pubmed: 23382691
Radiat Res. 2013 Apr;179(4):383-92
pubmed: 23373901
EMBO Rep. 2018 Mar;19(3):
pubmed: 29367285
Biomed Res Int. 2014;2014:470253
pubmed: 25276790
Cytokine Growth Factor Rev. 2017 Aug;36:39-48
pubmed: 28551321
Mol Cancer. 2017 Feb 16;16(1):41
pubmed: 28209166
Cell Death Dis. 2013 Jun 06;4:e654
pubmed: 23744354
Cancer Metastasis Rev. 2015 Jun;34(2):229-41
pubmed: 25939322
Oncogene. 2013 Sep 19;32(38):4586-92
pubmed: 23128397
Neoplasia. 2019 Feb;21(2):185-196
pubmed: 30591423
J Biol. 2003;2(2):13
pubmed: 12760745
J Cell Physiol. 2020 Mar;235(3):1877-1887
pubmed: 31397494
Transl Lung Cancer Res. 2016 Feb;5(1):16-25
pubmed: 26958490
Stem Cell Reports. 2019 Apr 9;12(4):712-727
pubmed: 30930246
Target Oncol. 2017 Aug;12(4):387-399
pubmed: 28664387
BMC Cancer. 2019 Jul 11;19(1):680
pubmed: 31296175
Nature. 2015 Jul 23;523(7561):486-90
pubmed: 26083756
Int J Mol Sci. 2017 Dec 01;18(12):
pubmed: 29194401
Stem Cells Int. 2018 May 2;2018:4598195
pubmed: 29853913
Sci Rep. 2019 Mar 1;9(1):3219
pubmed: 30824715
Am Soc Clin Oncol Educ Book. 2016;35:e450-8
pubmed: 27249753
J Exp Clin Cancer Res. 2018 Dec 17;37(1):318
pubmed: 30558661
J Cell Physiol. 2013 Aug;228(8):1720-6
pubmed: 23255165
Nat Med. 2018 May;24(5):580-590
pubmed: 29686426
Nature. 2009 Sep 10;461(7261):199-205
pubmed: 19741700
Brief Bioinform. 2018 Mar 1;19(2):286-302
pubmed: 27881428
Front Oncol. 2018 Sep 06;8:364
pubmed: 30237983
Nature. 2012 Sep 6;489(7414):75-82
pubmed: 22955617
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Rev Drug Discov. 2014 Jul;13(7):497-512
pubmed: 24981363
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
Cell Death Dis. 2013 Dec 05;4:e947
pubmed: 24309934
Cancers (Basel). 2011 May 20;3(2):2462-77
pubmed: 24212819
J Transl Med. 2014 Feb 24;12:54
pubmed: 24564996
Genome Biol. 2018 Apr 12;19(1):53
pubmed: 29650040
Epigenetics Chromatin. 2014 Nov 20;7(1):33
pubmed: 25473421
Cancers (Basel). 2018 Jul 27;10(8):
pubmed: 30060526
Clin Lung Cancer. 2016 Sep;17(5):350-361
pubmed: 27137346
Nature. 2019 Sep;573(7774):439-444
pubmed: 31485072
Cancer Lett. 2017 Oct 10;406:93-104
pubmed: 28797843
PLoS One. 2011;6(7):e21320
pubmed: 21789168
Biochem Biophys Res Commun. 2012 Sep 28;426(3):306-9
pubmed: 22925896
Curr Protoc Bioinformatics. 2017 Sep 13;59:11.15.1-11.15.21
pubmed: 28902396
Med Clin North Am. 2019 May;103(3):463-473
pubmed: 30955514
Int Immunopharmacol. 2017 May;46:210-219
pubmed: 28324831
Cell Death Dis. 2019 Sep 10;10(9):660
pubmed: 31506430
Oncotarget. 2018 Jan 24;9(15):12064-12078
pubmed: 29552293
Cell Cycle. 2013 Jun 1;12(11):1696-703
pubmed: 23656788
Nat Med. 2018 Sep;24(9):1469-1480
pubmed: 30038216
Cell Death Differ. 2019 Jul;26(7):1267-1282
pubmed: 30254376
J Transl Med. 2016 Feb 29;14:61
pubmed: 26928703

Auteurs

Claudia De Vitis (C)

Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, "Sapienza" University of Rome, 00161 Rome, Italy.

Giacomo Corleone (G)

SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Valentina Salvati (V)

Preclinical Models and New Therapeutic Agents Unit, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.

Francesca Ascenzi (F)

Tumor Immunology and Immunotherapy Unit, Department of Research, Advanced Diagnostic and Technological Innovation, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Matteo Pallocca (M)

SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Francesca De Nicola (F)

SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Maurizio Fanciulli (M)

SAFU Laboratory, Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Simona di Martino (S)

Pathology Unit, IRCSS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Sara Bruschini (S)

Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Christian Napoli (C)

Department of Medical Surgical Sciences and Translational Medicine, Sant'Andrea Hospital, "Sapienza" University of Rome, 00189 Rome, Italy.

Alberto Ricci (A)

Department of Clinical and Molecular Medicine, Division of Pneumology, Sapienza University of Rome, Sant'Andrea Hospital, 00189 Rome, Italy.

Massimiliano Bassi (M)

Department of Thoracic Surgery, University of Rome Sapienza, 00161 Rome, Italy.

Federico Venuta (F)

Department of Thoracic Surgery, University of Rome Sapienza, 00161 Rome, Italy.

Erino Angelo Rendina (EA)

Department of Thoracic Surgery, Sant'Andrea Hospital, "Sapienza" University of Rome, 00189 Rome, Italy.

Gennaro Ciliberto (G)

Scientific Direction, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Rita Mancini (R)

Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, "Sapienza" University of Rome, 00161 Rome, Italy.

Classifications MeSH